Overview

Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome

Status:
Withdrawn

Trial end date:
2014-01-01

Target enrollment:
0

Participant gender:
All

Summary

We plan to examine the gastrointestinal (GI) physiologic profile of Exenatide, a glucagon-like peptide (GLP-1) analog as a possible intestino-trophic growth factor capable of inducing small bowel adaptation and regeneration in patients with short bowel syndrome (SBS), with the potential to decrease parenteral nutrition dependence.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Mayo Clinic

Treatments:

Exenatide
Glucagon-Like Peptide 1
Lactulose
Mannitol

Criteria

Patients with short bowel syndrome, between the ages of 18-85 who are dependent on
parenteral nutrition for at least a year and are being closely followed by the Mayo Clinic
Home Parenteral Nutrition Program (HPN) with at least one multisystem evaluation a year.